Where we're headed
From research prototype to clinical-grade validation.
Five phases, staged honestly. The first three are complete and live. The fourth is new and early. The fifth — clinical-grade validation — is in progress.
Deterministic trial wedge Completed · Live
Three shipped workflows with auditable call statuses and CPIC + PharmVar provenance.
- Clopidogrel / CYP2C19
- Warfarin / CYP2C9 + VKORC1 + CYP4F2
- Simvastatin / SLCO1B1
Reviewer trust layer Completed · Live
Benchmarks, confidence calibration, reproducibility packs, evidence mapping, and reviewer reports.
- Evidence Sufficiency Layer with named refusals
- 12 R-rules · 10 V-rules · 9 U-rules
- 3 bias-detection kinds
Pilot operations Completed · Live
The production API and a public, zero-auth demo surface are running, with real 1000 Genomes sample mode.
- Production API on Azure Container Apps + MongoDB Atlas
- Deployed engine: anukriti-pgx-core 0.11.0, reported by the API itself
- Public zero-auth demo, 1000 Genomes sample mode
- Per-cohort outcome distributions
- Shareable run permalinks
Trial-planning surface New · Early
A cohort-level question for a trial sponsor: given the genetic architecture of two cohorts for one enzyme, at what fraction metabolised does a drug cross into a dosing liability. It takes no patient, no genotype and no VCF, and returns no dose.
- Trial-planning tool at /tools/fm-star, over four API routes
- Four named refusals: U-FM, U-PREV, U-CV, U-MODULE
- Of three audited probes, only S-warfarin (CYP2C9) passes the extraction audit
- Omeprazole and metoprolol therefore give upper bounds, not estimates
- Early work — not validated, and not offered as a clinical conclusion
Clinical-grade validation In progress
Deeper concordance benchmarking and an ancestry-specific evidence pack.
- PharmCAT concordance benchmark
- BCHE / Vysya founder-community wedge (Kerdoncuff 2025)
- CYP2D6 CNV calling via Cyrius
- Full AFR-specific evidence pack
- Partnership outreach: PharmVar, LASI-DAD, GenomeIndia